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Consanguinitya b s t r a c t
Progressive pseudorheumatoid dysplasia is a rare autosomal recessive spondyloepiphyseal dysplasia
characterized by predominant involvement of articular cartilage with progressive joint stiffness and
enlargement in the absence of inflammation. Short stature, joint contractures, gait disturbance, and sco-
liosis and/or kyphosis, resulting in abnormal posture and significant morbidity are generally seen over
time. This condition is caused by mutations of WISP3, a gene located on chromosome 6q21.
Ten patients pertaining to 3 families originated from Tunisia, Morocco and Senegal, with progressive
pseudorheumatoid dysplasia are described. Three exhibited marked muscle weakness resulting in
delayed diagnosis. Genetic studies of WISP3 in these three consanguineous kindred identified two muta-
tions, each at the homozygous state: c.624_625insA (p.C209Mfs*21), also named c.624dupA, in exon 4, in
the Tunisian and Senegalese patients, and c.48+2dupT, a splice donor site mutation in intron 1, in the
Moroccan patients.
The clinical features and the molecular studies of the WISP3 gene are discussed.
 2017 Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Progressive pseudorheumatoid dysplasia (PPRD), also referred
to as spondyloepiphyseal dysplasia tarda with progressive
arthropathy or Progressive pseudorheumatoid arthropathy of
childhood is a rare autosomal recessive skeletal disorder (OMIM
208230). It is characterized by an abnormal cartilage homeostasis
responsible for an axial and peripheral skeletal dysplasia, associ-
ated with pain, stiffness, and swelling of multiple joints mainly
wrists, fingers, hips, and knees. Walking difficulties often appear,
due to muscle weakness and flexion contractures and stiffness of
the hip and knee joints. The age of onset is in early childhood, with
most affected children presenting with disease features by the age
of 8-years. Adults with PPRD have usually short stature. The diag-
nosis is comforted radiologically: vertebral bodies are flattenedwith anterior ossification defects; the acetabular portion of the pel-
vis is irregular, the capital femoral epiphyses enlarged, the joint
spaces narrowed, and the ends of the proximal and middle pha-
langes are expanded. The articular space may be narrow, but
destructive bone changes and the inflammatory markers charac-
teristic of juvenile rheumatoid arthritis are always lacking. The dis-
order is caused by loss of function mutations of WISP3 (Wnt1-
inducible signaling pathway protein 3), a gene located on chromo-
some 6q21 (MIM 603400) [1,2].
WISP3 encodes a 354-amino-acid protein, a member of the CCN
(Connective tissue growth factor, Cysteine-rich 61, Nephroblas-
toma over-expressed) family of connective tissue growth factors,
known to be mostly extracellular-matrix associated proteins.
WISP3 is essential for maintaining cartilage integrity mainly by
regulating the expression of the type II collagen and aggrecan in
chondrocytes. WISP3 also is involved in regulation of cell migration
and adhesion, cell proliferation, differentiation, and survival in
connective tissues [1–3].
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bones, and the molecular studies of the WISP3 gene in consan-
guineous patients from Tunisia, Morocco and Senegal.2. Patients and methods
2.1. Ethical statement
This study was carried out with protocols approved by the
Ethics Committees of the Monastir-Sousse Hospitals and Universi-
ties (Tunisia), the Assistance-Publique Hôpitaux de Paris, France
and the Saint-Joseph University of Beirut (Lebanon). Informed con-
sent was obtained from the patients and/or their parents before
blood sampling and DNA analyses.2.2. Family 1
Patients of family 1 consist of 2 Tunisian consanguineous sibs
(Fig. 1A), originating from the Centre of Tunisia, now aged 28
and 21, respectively. Early developmental milestones were normal
for the affected siblings. Walking difficulties appeared between 13
and 18 years, due to flexion contractures of their hip and knee
joints, followed simultaneously, or, a few months later by painful
swelling of the interphalangeal joints with limited flexion, increas-
ing stiffness of the limb joints and spine with limited flexion and
extension of the knees, wrists, and elbows. Marked muscle weak-
ness, general wasting, and short stature (height below the 3rd per-
centile) were also noted.
The skeletal survey revealed broad ends of the short tubular
bones, especially in proximal phalanges; narrow joint spaces
between the carpal bones and the interphalangeal joints, flattened
vertebral bodies with rounded end plates, irregular upper and
lower plates, short pedicles, wide epiphyses of the knees, short
and wide femoral neck, large capital femoral epiphyses, flat and
irregular articular surfaces of the knees, and narrow joint spaces
(Fig. 2). Hips replacement was performed for both sibs when they
were 21 and 22 years.2.3. Family 2
Family 2 (Fig. 1B), is originated from Marakech Morocco. Par-
ents are second-degree cousins and are clinically healthy. The elder
affected sister developed difficulties in walking associated with
lower limb deformities at the age of 3. An initial diagnosis of rick-
ets was made but without any improvement after prolonged vita-
min D supplementation. Subsequently, joint contractures appeared
gradually in the hips, knees and fingers. Later on, marked general-
ized muscle weakness appeared. Although CK levels were normal, a
neuro-muscular disorder was suspected and a biopsy of the deltoid
muscle performed. Results of the latter were unconclusive. Motor
performance kept declining, and she became wheel-chair-bound
at age 13. Her younger sister, now aged 12, had a similar clinical
history but presented with additional, most probably fortuitous,
mild intellectual disability.
Both patients were only able to sit unsupported, had short sta-
ture (135 cm and 130 cm; largely below the 3rd percentile) and
presented with multiple joint deformities, particularly in the fin-
gers. Interestingly, neither of them ever complained of any specific
pain in any joints. Radiological examination revealed enlarged epi-
physes in the fingers, elbows, and knees; platyspondyly, scoliosis,
irregularities and destruction of the acetabula, and deformed
femoral heads.2.4. Family 3
Six consanguineous siblings, ranging from 6 to 21 years of age,
originating from Senegal, West Africa, were investigated (Fig. 1C).
The eldest affected child achieved normal motor milestones and
started complaining of difficulties in walking together with painful
ankles, hips and shoulders when he was 10 years old. In parallel, he
gradually developed mild muscle wasting in the distal part of the
lower limbs. Muscle weakness extended in the upper limbs over
the subsequent three years. Waddling gait and mild scapular wing-
ing were noted on examination. Electrophysiological studies per-
formed at age 15 revealed minor changes consistent with a
chronic neurogenic process. A muscle and nerve biopsy done
shortly afterwards turned out to be inconclusive.
On examination, the decline in motor functional abilities con-
trasted with the preservation of muscle strength and the absence
of sensory impairment. The patient continued complaining of occa-
sional pains in hips and knees, but never exhibited general symp-
toms such as fever or skin rashes. He was primarily considered to
have an axonal form of Charcot-Marie-Tooth disease. A closer clin-
ical re-evaluation at age 16 showed the presence of stiff joints in
the shoulders, elbows, hips and wrists whereas fingers and knees
appeared normal. No growth retardation was noted. Height was
at the 35th percentile. In contrast, the radiological evaluation
was very suggestive of a severe spondyloepiphyseal dysplasia with
marked diffuse osteoporosis, platyspondyly, and moderate
enlargement of epiphyses associated with mild narrowing of the
articular space in both hips. The course of the disease has been
slowly deteriorating since then, with enlargement of finger joints,
marked waddling gait and decline in motor abilities at age 19.
The other siblings had similar symptoms with some degree of
intra-familial variability whereas both parents were totally
healthy.2.5. Molecular studies
Given that clinical presentation and radiological abnormalities
were suggestive of PPRD, molecular studies of theWISP3 gene were
undertaken. EDTA blood samples were collected for genetic studies
and DNA was extracted from lymphocytes by standard methods
[4].
The coding sequence of WISP3 (GenBank Accession Numbers:
NM003880 and NM198239) gene was sequenced in all families
members, after their DNA was amplified by PCR (GeneAmp PCR
system 9700 from ThermoFisher). Primers sequences were
designed as previously described in Delague et al. [5], and checked
for specificity using BLAST (http://www.ncbi.nlm.nih.gov/blast/
bl2seq/wblast2.cgi), DNA sequences were obtained from UCSC or
Genbank databases. PCR reactions were performed using Taq
DNA polymerase (Invitrogen Life technologies, Carlsbad, CA,
USA). The amplification conditions for each PCR were 95 C for
5 min, followed by 35 cycles of 95 C for 30 s, the specific annealing
temperature for 30 s, and 72 C for 30 s, with a final extension of
10 min at 72 C.
PCR products from genomic DNA were purified using the GenE-
lute PCR clean-up kit (Sigma-Aldrich, USA), and both strands of the
resultant products were sequenced using the BigDye Terminator
v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA,
USA) under standard conditions. The labelled products were sub-
jected to electrophoresis on an ABI 3500 Genetic Analyzer
sequencing system Kit (Applied Biosystems, Foster City, CA, USA).
Electropherograms were analysed using Sequence Analysis Soft-
ware version 5.2 (Applied Biosystems, Foster City, CA) and com-
pared to reference sequences using ChromasPro version 1.7.5.4
(Technelysium, Queensland, Australia).
1A : Family  1 (Tunisian)
1C : Family 3 (Senegalese)1B : Family  2 (Moroccan)
Affected woman
Affected man
Figure 1. Pedigree of the 3 families.
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The exploration of the entire coding sequence of WISP3 allowed
the identification of the causative mutations in the patients.
Patients of family 1 (Tunisian family), were found homozygous
for an insert mutation c.624_625insA (p.C209Mfs*21), also named
c.624dupA, in exon 4 of WISP3. This frameshift mutation leads to
the substitution of the Cytosine at position 209 in a Methionine
creating a new reading frame which introduces a premature stop
codon 21 residues downstream. The Senegalese siblings (Family
3) were homozygous for the same mutation. The consanguineousMoroccan siblings (Family 2) were homozygous for the splicing
mutation c.48+2dupT in intron 1.
3. Discussion
Here, we report 3 families that fulfilled the clinical and radio-
logical criteria of PPRD. The latter has been estimated to occur in
approximately 1 per million people in European countries but
seems much more common in Turkey and the Middle East,
although its prevalence in these regions is unknown (5). The con-
dition in all regions is likely to be underdiagnosed because it is
often misdiagnosed as juvenile rheumatoid arthritis (JRA). PPRD
Figure 2. X-ray showing (A) wide epiphyses of the knee with flat and irregular
articular surfaces, and narrow joint spaces, and (B) the flattened vertebral bodies
with rounded end plates, irregular upper and lower plates, and short pedicles.
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extra-skeletal manifestations and articular bone erosion, and dif-
ferent radiological features. In PPRD there is no improvement with
steroids and immune-suppressive drugs.Often noted in some PPRD patients and in all the present cases,
is the muscle weakness, precipitating loss of ambulation, and lead-
ing to diagnostic mistakes. The muscular wasting might be
explained by accumulation of reactive oxygen species. Indeed, it
has been showed that WISP3 functions as a ligand and has a poten-
tial role in regulating the superoxide dismutase gene expression
[6] and the levels of reactive oxygen species (ROS) [7]. It is consid-
ered that disturbed expression of ROS contributes, in part, to the
pathology of many muscular dystrophies [8]. Thus, in PPRD, the
muscle weakness, due to abnormal levels of ROS, would be a direct
consequence of the mutations of WISP3.
The molecular diagnosis and the search of the mutations of
WISP3 allow to avoid clearly diagnosis mistakes and to confirm
without ambiguity a PPRD. The c.48+2dupT splicing mutation
found at the homozygous state in the Moroccan family has already
been reported in Jordanian patients [1,9,10], raising the question of
a possible founder effect owing to the Moslem conquests from the
Arabian Peninsula to the North Africa from the seventh century.
The mutation c.624_625insA (p.C209Mfs*21), found in the
Tunisian and Senegalese patients has been described in only four
patients at the compound heterozygous state: two were Chinese
[11], one from the USA [12] and the fourth from Poland [12]. The
premature stop codon, carried by our patients at the homozygous
state, generates a short truncated and not functional WISP3 pro-
tein, 230 amino-acids long, instead of 354. The parents inhabit
neighbouring villages and the historical data on both the families
support the hypothesis that the mutation would have segregated
in the two families from a common ancestor who lived in the late
fourteenth century in the region of Moknine and Sayada (Centre of
Tunisia, near the Mediterranean sea) [13].
In conclusions, we have reported the clinical and molecular
study of patients with PPRD from Tunisia, Morocco and, for the first
time, Senegal. The identification of the mutations in WISP3 gene, as
well as of a possible founder effect, presents a major interest in
these consanguineous families in order to put in place usefully
the genetic counselling and, if feasible, the prenatal diagnosis.Acknowledgements
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